Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma. In this open label phase II study (NCT00253630), patients with relapsed/refractory follicular lymphoma (FL),...
Saved in:
Published in | Journal of clinical oncology Vol. 29; no. 9; pp. 1198 - 1203 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Alexandria, VA
American Society of Clinical Oncology
20.03.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma.
In this open label phase II study (NCT00253630), patients with relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL), with ≤ 4 prior therapies were eligible. Oral vorinostat was administered at a dose of 200 mg twice daily on days 1 through 14 of a 21-day cycle until progression or unacceptable toxicity. The primary end point was objective response rate (ORR), with secondary end points of progression-free survival (PFS), time to progression, duration of response, safety, and tolerability.
All 35 eligible patients were evaluable for response. The median number of vorinostat cycles received was nine. ORR was 29% (five complete responses [CR] and five partial responses [PR]). For 17 patients with FL, ORR was 47% (four CR, four PR). There were two of nine responders with MZL (one CR, one PR), and no formal responders among the nine patients with MCL, although one patient maintained stable disease for 26 months. Median PFS was 15.6 months for patients with FL, 5.9 months for MCL, and 18.8 months for MZL. The drug was well-tolerated over long periods of treatment, with the most common grade 3 adverse events being thrombocytopenia, anemia, leucopenia, and fatigue.
Oral vorinostat is a promising agent in FL and MZL, with an acceptable safety profile. Further studies in combination with other active agents in this setting are warranted. |
---|---|
AbstractList | Purpose
We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma.
Patients and Methods
In this open label phase II study (NCT00253630), patients with relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL), with ≤ 4 prior therapies were eligible. Oral vorinostat was administered at a dose of 200 mg twice daily on days 1 through 14 of a 21-day cycle until progression or unacceptable toxicity. The primary end point was objective response rate (ORR), with secondary end points of progression-free survival (PFS), time to progression, duration of response, safety, and tolerability.
Results
All 35 eligible patients were evaluable for response. The median number of vorinostat cycles received was nine. ORR was 29% (five complete responses [CR] and five partial responses [PR]). For 17 patients with FL, ORR was 47% (four CR, four PR). There were two of nine responders with MZL (one CR, one PR), and no formal responders among the nine patients with MCL, although one patient maintained stable disease for 26 months. Median PFS was 15.6 months for patients with FL, 5.9 months for MCL, and 18.8 months for MZL. The drug was well-tolerated over long periods of treatment, with the most common grade 3 adverse events being thrombocytopenia, anemia, leucopenia, and fatigue.
Conclusion
Oral vorinostat is a promising agent in FL and MZL, with an acceptable safety profile. Further studies in combination with other active agents in this setting are warranted. PURPOSEWe performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma. PATIENTS AND METHODSIn this open label phase II study (NCT00253630), patients with relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL), with ≤ 4 prior therapies were eligible. Oral vorinostat was administered at a dose of 200 mg twice daily on days 1 through 14 of a 21-day cycle until progression or unacceptable toxicity. The primary end point was objective response rate (ORR), with secondary end points of progression-free survival (PFS), time to progression, duration of response, safety, and tolerability. RESULTSAll 35 eligible patients were evaluable for response. The median number of vorinostat cycles received was nine. ORR was 29% (five complete responses [CR] and five partial responses [PR]). For 17 patients with FL, ORR was 47% (four CR, four PR). There were two of nine responders with MZL (one CR, one PR), and no formal responders among the nine patients with MCL, although one patient maintained stable disease for 26 months. Median PFS was 15.6 months for patients with FL, 5.9 months for MCL, and 18.8 months for MZL. The drug was well-tolerated over long periods of treatment, with the most common grade 3 adverse events being thrombocytopenia, anemia, leucopenia, and fatigue. CONCLUSIONOral vorinostat is a promising agent in FL and MZL, with an acceptable safety profile. Further studies in combination with other active agents in this setting are warranted. We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma. In this open label phase II study (NCT00253630), patients with relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL), with ≤ 4 prior therapies were eligible. Oral vorinostat was administered at a dose of 200 mg twice daily on days 1 through 14 of a 21-day cycle until progression or unacceptable toxicity. The primary end point was objective response rate (ORR), with secondary end points of progression-free survival (PFS), time to progression, duration of response, safety, and tolerability. All 35 eligible patients were evaluable for response. The median number of vorinostat cycles received was nine. ORR was 29% (five complete responses [CR] and five partial responses [PR]). For 17 patients with FL, ORR was 47% (four CR, four PR). There were two of nine responders with MZL (one CR, one PR), and no formal responders among the nine patients with MCL, although one patient maintained stable disease for 26 months. Median PFS was 15.6 months for patients with FL, 5.9 months for MCL, and 18.8 months for MZL. The drug was well-tolerated over long periods of treatment, with the most common grade 3 adverse events being thrombocytopenia, anemia, leucopenia, and fatigue. Oral vorinostat is a promising agent in FL and MZL, with an acceptable safety profile. Further studies in combination with other active agents in this setting are warranted. |
Author | Stephen J. Forman Deron Matsuoka Auayporn Nademanee Paul Frankel Arnold J. Rotter Igor Espinoza-Delgado Leslie Popplewell Jasmine Zain Bernadette Pulone Edward Newman Vinod Pullarkat David Gandara Mark Kirschbaum Maria Delioukina |
Author_xml | – sequence: 1 givenname: Mark surname: KIRSCHBAUM fullname: KIRSCHBAUM, Mark organization: City of Hope, Duarte, United States – sequence: 2 givenname: Paul surname: FRANKEL fullname: FRANKEL, Paul organization: City of Hope, Duarte, United States – sequence: 3 givenname: Auayporn surname: NADEMANEE fullname: NADEMANEE, Auayporn organization: City of Hope, Duarte, United States – sequence: 4 givenname: Stephen J surname: FORMAN fullname: FORMAN, Stephen J organization: City of Hope, Duarte, United States – sequence: 5 givenname: David surname: GANDARA fullname: GANDARA, David organization: City of Hope, Duarte, United States – sequence: 6 givenname: Edward surname: NEWMAN fullname: NEWMAN, Edward organization: City of Hope, Duarte, United States – sequence: 7 givenname: Leslie surname: POPPLEWELL fullname: POPPLEWELL, Leslie organization: City of Hope, Duarte, United States – sequence: 8 givenname: Jasmine surname: ZAIN fullname: ZAIN, Jasmine organization: City of Hope, Duarte, United States – sequence: 9 givenname: Maria surname: DELIOUKINA fullname: DELIOUKINA, Maria organization: City of Hope, Duarte, United States – sequence: 10 givenname: Vinod surname: PULLARKAT fullname: PULLARKAT, Vinod organization: City of Hope, Duarte, United States – sequence: 11 givenname: Deron surname: MATSUOKA fullname: MATSUOKA, Deron organization: City of Hope, Duarte, United States – sequence: 12 givenname: Bernadette surname: PULONE fullname: PULONE, Bernadette organization: City of Hope, Duarte, United States – sequence: 13 givenname: Arnold J surname: ROTTER fullname: ROTTER, Arnold J organization: City of Hope, Duarte, United States – sequence: 14 givenname: Igor surname: ESPINOZA-DELGADO fullname: ESPINOZA-DELGADO, Igor organization: City of Hope, Duarte, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23985052$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21300924$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkc1vEzEQxS1URNPCnRPyBXra4I911ntBqiJogwJFpSBu1thrJ1t27WBvinLgf8erhACn0ej95s3Y7wyd-OAtQs8pmVJGyOv385spI7njbEp5LR-hCRWsKqpKiBM0IRVnBZX82yk6S-meEFpKLp6gU0Y5ITUrJ-jXpzUkixcL_HnYNjscHP4aYutDGmDALkR8Fy0MvfXDqN3aDjbJNjgLt9ZFMEOIO7zwTehG5GPwxXVoVt9bf5Hwctdv1qEHDL7BH8APncVz23VH4Sl67KBL9tmhnqMv797eza-L5c3VYn65LIyY1UPhNGmammgH0mlaOa21k9ZxZzSBemYq4hznQtsSmIASSkOAzXTDpdCybAg_R2_2vput7m1j8qkROrWJbQ9xpwK06n_Ft2u1Cg-KE8llJbLBxcEghh9bmwbVt8nkp4C3YZuUFJWkrKrrTJI9aWJIKVp33EKJGkNTOTQ1hqY4U2NoeeTFv9cdB_6klIGXBwCSgS5_uzdt-stlE0EEy9yrPbduV-ufbbQq9dB12ZapexNYrWpFad74G_cVsew |
CitedBy_id | crossref_primary_10_3389_fonc_2022_874645 crossref_primary_10_1002_mco2_181 crossref_primary_10_1007_s40265_020_01446_1 crossref_primary_10_1007_s12272_015_0571_1 crossref_primary_10_1021_mp200329f crossref_primary_10_1080_10428194_2018_1520986 crossref_primary_10_1016_j_ejmech_2017_03_079 crossref_primary_10_1016_j_jtct_2022_05_021 crossref_primary_10_1002_acg2_74 crossref_primary_10_3109_10428194_2013_840888 crossref_primary_10_1182_blood_2015_11_624312 crossref_primary_10_1111_bjh_16914 crossref_primary_10_1158_1078_0432_CCR_15_0624 crossref_primary_10_1182_bloodadvances_2020003566 crossref_primary_10_1016_j_blre_2017_08_002 crossref_primary_10_18632_genesandcancer_65 crossref_primary_10_18632_oncotarget_8961 crossref_primary_10_1080_15592294_2017_1282587 crossref_primary_10_1080_17460441_2016_1230095 crossref_primary_10_1038_s41392_020_0113_2 crossref_primary_10_1097_PPO_0000000000000463 crossref_primary_10_1111_bjh_19064 crossref_primary_10_1016_j_cct_2023_107083 crossref_primary_10_1007_s11864_018_0550_0 crossref_primary_10_1517_17425255_2013_754011 crossref_primary_10_1159_000533944 crossref_primary_10_4161_cc_25914 crossref_primary_10_1186_s12935_017_0439_1 crossref_primary_10_1007_s10495_015_1125_1 crossref_primary_10_1007_s00280_011_1762_1 crossref_primary_10_1074_jbc_M113_472563 crossref_primary_10_3389_fcell_2020_576391 crossref_primary_10_1016_j_yexcr_2018_05_038 crossref_primary_10_1016_j_bbmt_2011_11_012 crossref_primary_10_2217_epi_13_39 crossref_primary_10_1007_s11912_018_0687_9 crossref_primary_10_1016_j_jaad_2014_12_010 crossref_primary_10_1007_s00441_014_1912_y crossref_primary_10_1517_13543784_2016_1164140 crossref_primary_10_1053_j_seminhematol_2011_05_001 crossref_primary_10_1007_s13402_019_00439_x crossref_primary_10_1038_bcj_2015_89 crossref_primary_10_18632_oncotarget_25588 crossref_primary_10_2217_ijh_13_67 crossref_primary_10_1080_17474086_2020_1850252 crossref_primary_10_1038_onc_2011_552 crossref_primary_10_1097_MOH_0b013e328347786d crossref_primary_10_1111_bjh_12819 crossref_primary_10_1182_blood_2018_05_851667 crossref_primary_10_1016_S1470_2045_11_70327_8 crossref_primary_10_1517_21678707_2015_997209 crossref_primary_10_1016_j_revmed_2022_05_009 crossref_primary_10_3109_10428194_2012_658571 crossref_primary_10_3324_haematol_2021_278717 crossref_primary_10_1007_s00280_016_3005_y crossref_primary_10_1007_s10549_012_2171_9 crossref_primary_10_1182_blood_2016_12_753145 crossref_primary_10_1093_annonc_mdw029 crossref_primary_10_1002_ijc_28321 crossref_primary_10_1016_j_beha_2017_11_003 crossref_primary_10_1186_s13148_023_01452_6 crossref_primary_10_1016_j_ejmech_2020_112291 crossref_primary_10_1007_s11899_014_0221_6 crossref_primary_10_1172_JCI61272 crossref_primary_10_1080_10428194_2016_1248965 crossref_primary_10_1097_CAD_0000000000001165 crossref_primary_10_1016_j_blre_2012_09_004 crossref_primary_10_1182_blood_2014_06_582650 crossref_primary_10_1182_blood_2017_08_737361 crossref_primary_10_1111_j_1349_7006_2011_02127_x crossref_primary_10_1002_ajh_26288 crossref_primary_10_1016_j_hoc_2020_03_002 crossref_primary_10_1016_j_ijcard_2016_06_012 crossref_primary_10_1038_cddis_2013_159 crossref_primary_10_1016_j_matbio_2018_02_015 crossref_primary_10_3390_ijms232113657 crossref_primary_10_3390_cancers13040641 crossref_primary_10_1634_theoncologist_2019_0138 crossref_primary_10_2147_BLCTT_S282247 crossref_primary_10_1111_bjh_14094 crossref_primary_10_3389_fcell_2021_805195 crossref_primary_10_1016_j_ejphar_2017_02_035 crossref_primary_10_1080_10428194_2022_2164194 crossref_primary_10_1016_j_beha_2016_07_004 crossref_primary_10_1038_s41571_019_0190_8 crossref_primary_10_1016_j_tetlet_2012_10_113 crossref_primary_10_1097_CCO_0000000000000010 crossref_primary_10_1007_s00280_020_04229_3 crossref_primary_10_1080_10428194_2019_1672052 crossref_primary_10_1007_s10637_015_0290_y crossref_primary_10_1016_j_clml_2018_05_023 crossref_primary_10_18632_oncotarget_10033 crossref_primary_10_1182_asheducation_2013_1_568 crossref_primary_10_1093_jnci_djw263 crossref_primary_10_1016_j_critrevonc_2020_103038 crossref_primary_10_1093_hmg_ddt660 crossref_primary_10_3109_10428194_2013_780288 crossref_primary_10_1177_1078155219895079 crossref_primary_10_3109_10428194_2014_982638 crossref_primary_10_3109_10428194_2015_1063143 crossref_primary_10_1177_20406207231173485 crossref_primary_10_1007_s11912_015_0464_y crossref_primary_10_1097_MOH_0000000000000437 crossref_primary_10_1016_j_bbrc_2015_06_145 crossref_primary_10_1016_j_leukres_2012_02_021 crossref_primary_10_1177_107327481201900307 crossref_primary_10_1016_j_molonc_2016_06_001 crossref_primary_10_14694_EdBook_AM_2015_35_e365 crossref_primary_10_1016_j_clml_2011_03_029 crossref_primary_10_1016_j_clml_2014_03_006 crossref_primary_10_1080_17474086_2017_1303374 crossref_primary_10_1080_10428194_2020_1762883 crossref_primary_10_1111_bjh_13318 crossref_primary_10_1007_s12094_022_02820_z crossref_primary_10_1038_leu_2013_38 crossref_primary_10_18632_oncotarget_28258 crossref_primary_10_1182_blood_2020009855 crossref_primary_10_3390_cancers14092158 crossref_primary_10_3389_fgene_2019_00986 crossref_primary_10_1111_bjh_15283 crossref_primary_10_1038_s41572_019_0132_x crossref_primary_10_1517_13543784_2013_815165 crossref_primary_10_1038_onc_2012_81 crossref_primary_10_1586_14737140_2015_1002773 crossref_primary_10_4155_cli_13_36 crossref_primary_10_3109_10428194_2015_1075019 crossref_primary_10_1038_ncomms8390 crossref_primary_10_1080_17474086_2021_1856652 crossref_primary_10_3390_ijms23010253 crossref_primary_10_3109_10428194_2011_608448 crossref_primary_10_1016_j_leukres_2011_12_005 crossref_primary_10_1039_C8BM00437D crossref_primary_10_1177_2040620712453595 crossref_primary_10_1111_bjh_13016 crossref_primary_10_1016_j_bbcan_2013_04_001 crossref_primary_10_18632_oncotarget_10716 crossref_primary_10_1111_j_1600_065X_2012_01112_x crossref_primary_10_1016_j_hoc_2016_07_014 crossref_primary_10_1038_cddis_2015_394 crossref_primary_10_1016_j_semcancer_2011_09_008 crossref_primary_10_1038_icb_2011_100 crossref_primary_10_1097_MJT_0000000000000164 crossref_primary_10_1016_j_molonc_2012_09_004 crossref_primary_10_1097_PPO_0000000000000444 crossref_primary_10_1080_21678707_2016_1198255 crossref_primary_10_1517_13543784_2016_1152259 crossref_primary_10_1007_s12975_015_0421_y crossref_primary_10_1016_j_beha_2012_04_001 crossref_primary_10_1200_JCO_2015_63_5904 |
Cites_doi | 10.1200/JCO.2004.04.020 10.1158/1078-0432.CCR-08-2647 10.1182/blood-2007-10-117762 10.1182/blood.V114.22.2726.2726 10.1200/JCO.2003.08.054 10.1200/jco.2010.28.15_suppl.8086 10.1182/blood-2003-02-0622 10.1200/JCO.2003.09.047 10.1182/blood-2002-11-3514 10.1007/s00277-009-0777-8 10.1038/sj.onc.1210620 10.1016/j.canlet.2008.11.012 10.1200/JCO.2008.21.1169 10.1073/pnas.180316197 10.1200/JCO.1993.11.4.644 10.1200/JCO.1999.17.4.1244 10.1200/JCO.2007.12.5070 10.1128/MCB.26.7.2782-2790.2006 10.1200/JCO.2002.11.068 10.1016/j.canlet.2009.02.042 10.1182/blood.V96.12.3847 10.1111/j.1349-7006.2009.01360.x 10.1200/JCO.2008.17.0001 10.1182/blood-2003-04-1205 10.1073/pnas.0712051105 10.1016/j.hoc.2007.06.011 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS 2011 by American Society of Clinical Oncology |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: 2011 by American Society of Clinical Oncology |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1200/JCO.2010.32.1398 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 1203 |
ExternalDocumentID | 10_1200_JCO_2010_32_1398 21300924 23985052 jco29_9_1198 |
Genre | Clinical Trial, Phase II Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: U01-CA-62505 – fundername: NCI NIH HHS grantid: U01 CA062505 – fundername: NCI NIH HHS grantid: N01-CM-62209 – fundername: NCI NIH HHS grantid: P30-CA-033572 – fundername: NCI NIH HHS grantid: N01CM62209 – fundername: NCI NIH HHS grantid: P30 CA033572 |
GroupedDBID | - 0R 2WC 34G 39C 3O- 4.4 53G 55 5GY 5RE 8F7 AAPEM AARDX AAWTL AAYEP ABFLS ABOCM ACDCL ACGFS ADBBV ADKWQ AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL CS3 DIK EBS EJD F5P FD8 FH7 GX1 H13 HZ IH2 K-O KQ8 L7B LSO N9A O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS VH1 WH7 X7M YCJ ZA5 --- .55 .GJ 08G 08P 08R 0R~ 18M 29K 5VS 8WZ A6W AAKAS AAQQT AAUGY AAYOK ACGFO ADZCM AEGXH AI. AIAGR ASPBG AVWKF AZFZN C45 D-I EX3 F9R FBNNL FEDTE HZ~ IPNFZ IQODW J5H MJL N4W NTWIH QTD R1G RIG RLZ TEORI TR2 UHU VVN WOQ WOW YFH YQY ZGI ABJNI ACGUR CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c569t-fb0dd90bfa8fb17fbbbf8ef3fcb0a96c70ff335be4a25a4a4c0a26bd385b84d03 |
ISSN | 0732-183X |
IngestDate | Tue Sep 17 21:11:49 EDT 2024 Wed Jul 24 16:17:05 EDT 2024 Fri Aug 23 00:39:40 EDT 2024 Thu May 23 23:17:45 EDT 2024 Sun Oct 22 16:09:17 EDT 2023 Tue Jan 05 20:16:28 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | Antineoplastic agent Relapse Treatment resistance B cell neoplasm Malignant hemopathy B-Lymphocyte Non Hodgkin lymphoma Histone deacetylase inhibitor Cancerology Treatment Lymphoproliferative syndrome Vorinostat Phase II trial Mantle cell lymphoma Indolent lymphoma Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c569t-fb0dd90bfa8fb17fbbbf8ef3fcb0a96c70ff335be4a25a4a4c0a26bd385b84d03 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://europepmc.org/articles/pmc3083875?pdf=render |
PMID | 21300924 |
PQID | 857812799 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3083875 proquest_miscellaneous_857812799 crossref_primary_10_1200_JCO_2010_32_1398 pubmed_primary_21300924 pascalfrancis_primary_23985052 highwire_smallpub2_jco29_9_1198 |
ProviderPackageCode | RHI |
PublicationCentury | 2000 |
PublicationDate | 2011-03-20 |
PublicationDateYYYYMMDD | 2011-03-20 |
PublicationDate_xml | – month: 03 year: 2011 text: 2011-03-20 day: 20 |
PublicationDecade | 2010 |
PublicationPlace | Alexandria, VA |
PublicationPlace_xml | – name: Alexandria, VA – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2011 |
Publisher | American Society of Clinical Oncology |
Publisher_xml | – name: American Society of Clinical Oncology |
References | 19817748 - Cancer Sci. 2010 Jan;101(1):196-200 10561185 - J Clin Oncol. 1999 Apr;17(4):1244 19582455 - Ann Hematol. 2010 Jan;89(1):25-33 19359091 - Cancer Lett. 2009 Aug 8;280(2):125-33 20068103 - Clin Cancer Res. 2010 Jan 15;16(2):719-26 12743154 - J Clin Oncol. 2003 May 15;21(10):1996-2003 11090069 - Blood. 2000 Dec 1;96(12):3847-56 17908623 - Hematol Oncol Clin North Am. 2007 Oct;21(5):841-54 18347343 - Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4796-801 17694093 - Oncogene. 2007 Aug 13;26(37):5541-52 19111391 - Cancer Lett. 2009 Aug 8;280(2):145-53 15483015 - J Clin Oncol. 2004 Dec 1;22(23):4711-6 3329634 - IARC Sci Publ. 1987;(82):1-406 19805688 - J Clin Oncol. 2009 Nov 10;27(32):5404-9 18626004 - J Clin Oncol. 2008 Sep 20;26(27):4473-9 12750161 - Blood. 2003 Oct 1;102(7):2351-7 10954755 - Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9 12488409 - J Clin Oncol. 2002 Dec 15;20(24):4649-54 14506144 - Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 8478660 - J Clin Oncol. 1993 Apr;11(4):644-51 12963703 - J Clin Oncol. 2003 Oct 15;21(20):3744-53 12893748 - Blood. 2003 Nov 15;102(10):3521-9 16537920 - Mol Cell Biol. 2006 Apr;26(7):2782-90 12531799 - Blood. 2003 May 15;101(10):4055-62 18182663 - J Clin Oncol. 2008 Jan 10;26(2):204-10 18349321 - Blood. 2008 May 15;111(10):5093-100 B20 B21 B22 B24 B25 B26 B27 B28 Breslow NE (B23) 1987; 82 Kelly WK (B19) 2003; 9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B1 B2 B3 B4 B5 B6 B7 B8 B9 |
References_xml | – ident: B9 doi: 10.1200/JCO.2004.04.020 – ident: B28 doi: 10.1158/1078-0432.CCR-08-2647 – ident: B15 doi: 10.1182/blood-2007-10-117762 – ident: B26 doi: 10.1182/blood.V114.22.2726.2726 – ident: B4 doi: 10.1200/JCO.2003.08.054 – volume: 82 start-page: 1 year: 1987 ident: B23 publication-title: IARC Sci Publ contributor: fullname: Breslow NE – ident: B25 doi: 10.1200/jco.2010.28.15_suppl.8086 – ident: B8 doi: 10.1182/blood-2003-02-0622 – ident: B3 doi: 10.1200/JCO.2003.09.047 – ident: B17 doi: 10.1182/blood-2002-11-3514 – volume: 9 start-page: 3578 year: 2003 ident: B19 publication-title: Clin Cancer Res contributor: fullname: Kelly WK – ident: B24 doi: 10.1007/s00277-009-0777-8 – ident: B18 doi: 10.1038/sj.onc.1210620 – ident: B11 doi: 10.1016/j.canlet.2008.11.012 – ident: B27 doi: 10.1200/JCO.2008.21.1169 – ident: B14 doi: 10.1073/pnas.180316197 – ident: B1 doi: 10.1200/JCO.1993.11.4.644 – ident: B22 doi: 10.1200/JCO.1999.17.4.1244 – ident: B7 doi: 10.1200/JCO.2007.12.5070 – ident: B10 doi: 10.1128/MCB.26.7.2782-2790.2006 – ident: B2 doi: 10.1200/JCO.2002.11.068 – ident: B13 doi: 10.1016/j.canlet.2009.02.042 – ident: B12 doi: 10.1182/blood.V96.12.3847 – ident: B20 doi: 10.1111/j.1349-7006.2009.01360.x – ident: B6 doi: 10.1200/JCO.2008.17.0001 – ident: B5 doi: 10.1182/blood-2003-04-1205 – ident: B16 doi: 10.1073/pnas.0712051105 – ident: B21 doi: 10.1016/j.hoc.2007.06.011 |
SSID | ssj0014835 |
Score | 2.4793646 |
Snippet | We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with... Purpose We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients... PURPOSEWe performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis highwire |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1198 |
SubjectTerms | Administration, Oral Adult Aged Antineoplastic Agents - therapeutic use Biological and medical sciences Drug Resistance, Neoplasm - drug effects Female Hematologic and hematopoietic diseases Humans Hydroxamic Acids - therapeutic use Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, B-Cell, Marginal Zone - drug therapy Lymphoma, B-Cell, Marginal Zone - pathology Lymphoma, Follicular - drug therapy Lymphoma, Follicular - pathology Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - pathology Male Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Original Reports Remission Induction Salvage Therapy Survival Rate Treatment Outcome Tumors |
Title | Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma |
URI | http://jco.ascopubs.org/content/29/9/1198.abstract https://www.ncbi.nlm.nih.gov/pubmed/21300924 https://search.proquest.com/docview/857812799 https://pubmed.ncbi.nlm.nih.gov/PMC3083875 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAvCMYtXIYf0BDqMhLn_liqQsu2rhot6ltkJzEDdcm0tA9F4qfyXzi24yQtQ1xeoqonTdJ-X8-xfT6fg9DLMPGZnVFqOpnLTGAIN6PUSkxObJpRHvopkwLZsT-cuR_m3rzT-dFSLa2W7DD5du2-kv9BFd4DXMUu2X9Atr4ovAGvAV84AsJw_CuMJ-cQg7qjkVQDylT5J6GnK8QuIakfnNYycllzZEEvSxhgguEs41ey084aPIQo6gSnjIvcHBbpZ9mgKyi7x2tAuriglRYjhzt2-2KpTxt-M7CtN1sWebKxaH80OvvYH77tzU62dwkJveDR4HhbqjgWNOmNB1Kx2VvRNUwWajLD9BVsLaValeFKmzVZxyRWQzqdm9JCVSFE0Y962n5U5RcDh5jgieYqhFV-mwQwUVAVf7Vjr5ZSFIGjlpe2bdX5uor4NpFlFn6NJkQ2yv6aFEoC6JBDGC-HTeTUaoGtgFrLHEVtRdEo8Aa6SYLIE2sD7-e1Agkmoqr_q_4-VRYd7vpm-56boyZdyVoIeWkJvxJXTViumyVti31bo6fpXXSnYgfuKQ7fQ50s30W3Tiphxy7an6gS6usDPG12BJYHeB9PmuLq6_vou-Q8Ho2w5DwuOG44j4HzuOa8sGnOYzA0nMea87jF-Vcl1sTGwHisGI8F42vDAzR7N5j2h2bVQsRMPD9ampxZaRpZjNOQMzvgjDEeZtzhCbNo5CeBxbnjeCxzKfGoS93EosRnqRN6LHRTy3mIdvIizx4jnFGXJzaLMmpxN_XAA3M4nfOIBLaXcMtArzVE8aWqFBOLGTYR6eL-aSzgjB0SCzgN9EJjGJcXdLEAiEgMoJMojmJBTwPtbUBbX1JzykBYYx1DRBBpPppnxaqMQwjCNvAtMtAjBX3zYZG8johroGCDFPUJotj8piX_ci6LzjswVwsD78mfnusput38xZ-hneXVKnsO4_Yl25Ps_wkJmPRe |
link.rule.ids | 230,315,786,790,891,27957,27958 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+II+Study+of+Vorinostat+for+Treatment+of+Relapsed+or+Refractory+Indolent+Non-Hodgkin%27s+Lymphoma+and+Mantle+Cell+Lymphoma&rft.jtitle=Journal+of+clinical+oncology&rft.au=KIRSCHBAUM%2C+Mark&rft.au=FRANKEL%2C+Paul&rft.au=NADEMANEE%2C+Auayporn&rft.au=FORMAN%2C+Stephen+J&rft.date=2011-03-20&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=29&rft.issue=9&rft.spage=1198&rft.epage=1203&rft_id=info:doi/10.1200%2Fjco.2010.32.1398&rft.externalDBID=n%2Fa&rft.externalDocID=23985052 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |